365 related articles for article (PubMed ID: 16230074)
41. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
42. [Investigation of entecavir medication of chronic hepatitis B patients in the Chongqing area who failed lamivudine treatment].
Wang ZY; Zhang DZ; Shi XF; Zhou Z; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):13-5. PubMed ID: 17244451
[TBL] [Abstract][Full Text] [Related]
43. [A study of the dosage and efficacy of entecavir for treating hepatitis B virus].
Yao GB; Zhang DF; Wang BE; Xu DZ; Zhou XQ; Lei BJ
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):484-7. PubMed ID: 16042878
[TBL] [Abstract][Full Text] [Related]
44. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B.
Goulis I; Dalekos GN
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):855-9. PubMed ID: 19053898
[TBL] [Abstract][Full Text] [Related]
45. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U
Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
[TBL] [Abstract][Full Text] [Related]
46. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
47. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
48. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
Chien RN; Liaw YF
Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
[TBL] [Abstract][Full Text] [Related]
49. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
50. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.
Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX
Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683
[TBL] [Abstract][Full Text] [Related]
51. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
Bozkaya H; Yurdaydin C; Idilman R; Tüzün A; Cinar K; Erkan O; Bozdayi AM; Erden E; Uzun Y; Cetinkaya H; Uzunalimoglu O
Antivir Ther; 2005; 10(2):319-25. PubMed ID: 15865226
[TBL] [Abstract][Full Text] [Related]
52. [A clinical study of viral dynamic change in patients with hepatitis B e antigen positive chronic hepatitis B by lamivudine treatment].
Xu JH; Yu YY; Si CW; Chen XY; Han ZH; Chen Y; Li XY
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(41):2902-5. PubMed ID: 20137646
[TBL] [Abstract][Full Text] [Related]
53. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
[TBL] [Abstract][Full Text] [Related]
55. A review of entecavir in the treatment of chronic hepatitis B infection.
Rivkin A
Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
Lee KS; Kweon YO; Um SH; Kim BH; Lim YS; Paik SW; Heo J; Lee HJ; Kim DJ; Kim TH; Lee YS; Byun KS; Kim D; Lee MS; Yu K; Suh DJ
Clin Mol Hepatol; 2017 Dec; 23(4):331-339. PubMed ID: 28946736
[TBL] [Abstract][Full Text] [Related]
57. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
Yeh CT; Hsu CW; Chen YC; Liaw YF
J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
[TBL] [Abstract][Full Text] [Related]
58. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure].
Shu X; Xu QH; Chen N; Zhang K; Li G
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):481-3. PubMed ID: 19544652
[TBL] [Abstract][Full Text] [Related]
59. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.
Zhang X; Lin SM; Ye F; Chen TY; Liu M; Chen YR; Zheng SQ; Zhao YR; Zhang SL
J Viral Hepat; 2011 Jul; 18(7):e184-90. PubMed ID: 21692931
[TBL] [Abstract][Full Text] [Related]
60. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
